Full Breakdown
Employers Plan to Drop GLP-1 Weight-Loss Drug Coverage in 2027
6/11/2026, 9:49:33 PM
Employers Plan to Drop GLP-1 Weight-Loss Coverage in 2027
A 2024 Business Group on Health (BGH) survey found 10 % of employers covering GLP-1 drugs for weight management plan to drop coverage in 2027; Mercer reported 5 % of firms with >500 employees plan the same. Cigna stopped covering the drugs for its workforce in July, directing members to buy them at discounted rates via manufacturer sites.
Drivers and Context
GLP-1 therapies—injectable Wegovy and Zepbound from Novo Nordisk and oral Wegovy pill and Foundayo from Eli Lilly—have moved from diabetes to chronic weight management. Priced at $149 per month, the oral options attract users who avoid injections, expanding the patient pool and extending treatment, raising total spend despite lower unit costs.
Data Snapshot
In 2026, 67 % of large employers covered GLP-1s (BGH). Mercer says 44 % of firms with >500 employees cover them for obesity. SHRM finds 72 % of current carriers expect to maintain coverage in 2027, while 87 % anticipate higher demand from oral GLP-1s and only 9 % foresee price cuts.
Official Responses
BGH notes employers are examining pharmacy-benefit-manager contracts and direct-to-consumer pricing to cut costs. Cigna cited discounted purchases via manufacturer portals and TrumpRx.gov as justification for its cut. Mercer said many firms have not realized expected PBM savings, and Aon projects a modest decline in overall GLP-1 coverage next year.
Criticism & Cost Concerns
Employers argue rising pharmacy costs outweigh GLP-1 benefits. Sara Izadi, chief clinical officer at Judi Health, said employers “face mounting pressure to manage rising costs and have yet to see clear ROI from GLP-1 utilization.” BGH president Ellen Kelsay warned GLP-1s are driving double-digit cost increases.
Conflicting Survey Findings
BGH reports 10 % of employers likely to stop coverage, while Mercer finds 5 % of large firms planning to drop it. SHRM indicates 72 % of current carriers expect to maintain coverage, showing divergent subsets.
Verbatim Quotes
- “Even though we have seen the unit cost come down, the patient population keeps growing,” — Louis Zollo, Pharmacy Practice Leader, Segal
- “Employers continue to face mounting pressure to manage rising pharmacy and healthcare costs and, in many cases, have yet to see clear ROI from GLP-1 utilization in their own employee population,” — Sara Izadi, Chief Clinical Officer, Judi Health
- “For those who weren’t comfortable with weekly injections, a once-daily pill is much easier to use and understand,” — Nick Conway, President, Rx Solutions, NFP
- “There’s going to be more people taking these drugs, so on aggregate this still represents a major cost driver for employers.” — Dan Mendelson, CEO, Morgan Health
Outlook
Employers are tightening eligibility by requiring biometric thresholds, participation in weight-management programs, and exploring alternative funding models. While some plan to drop coverage, most expect to manage demand through stricter utilization controls. The introduction of oral GLP-1s is projected to increase overall demand, potentially reshaping future pricing negotiations and coverage policies.
